TipRanks
Advertisement
Advertisement

VOR Stock Latest News

Vor Bio completes enrollment in UPSTREAM MG trial
The FlyVor Bio completes enrollment in UPSTREAM MG trial
15d ago
VOR
Vor Bio files automatic mixed securities shelf
PremiumThe Fly
Vor Bio files automatic mixed securities shelf
19d ago
VOR
Vor Bio price target raised to $27 from $18 at Wedbush
PremiumThe Fly
Vor Bio price target raised to $27 from $18 at Wedbush
1M ago
VOR
Vor Bio reports Q2 EPS ($1.16) vs. ($251.24) last year
PremiumThe Fly
Vor Bio reports Q2 EPS ($1.16) vs. ($251.24) last year
1M ago
VOR
Vor Bio sees cash runway into early 2029
PremiumThe Fly
Vor Bio sees cash runway into early 2029
1M ago
VOR
Vor Biopharma Adds Industry Veteran David Zaccardelli to Board
PremiumCompany AnnouncementsVor Biopharma Adds Industry Veteran David Zaccardelli to Board
3M ago
8K
VOR
Vor Biopharma shareholders back directors and governance measures
Premium
Company Announcements
Vor Biopharma shareholders back directors and governance measures
3M ago
8K
VOR
Vor Bio gains boost from telitacicept IgA nephropathy approval
Premium
Company Announcements
Vor Bio gains boost from telitacicept IgA nephropathy approval
4M ago
8K
VOR
Vor Bio announces China NMPA approval for telitacicept
PremiumThe Fly
Vor Bio announces China NMPA approval for telitacicept
4M ago
VOR
Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar
PremiumCompany Announcements
Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar
4M ago
VOR
Vor Biopharma: Buy Rating Reiterated on Strong Telitacicept Validation and Autoimmune Growth Runway; $31 Price Target Unchanged
PremiumRatings
Vor Biopharma: Buy Rating Reiterated on Strong Telitacicept Validation and Autoimmune Growth Runway; $31 Price Target Unchanged
4M ago
VOR
Vor Bio price target raised to $18 from $15 at Wedbush
PremiumThe Fly
Vor Bio price target raised to $18 from $15 at Wedbush
4M ago
VOR
Vor Biopharma Advances Phase 3 Telitacicept Trial in Myasthenia Gravis, Keeping Investor Focus High
PremiumCompany AnnouncementsVor Biopharma Advances Phase 3 Telitacicept Trial in Myasthenia Gravis, Keeping Investor Focus High
5M ago
VOR
Vor Bio files to sell 5.34M shares of common stock for holders
Premium
The Fly
Vor Bio files to sell 5.34M shares of common stock for holders
5M ago
VOR
Clene, Lovesac, HDFC Bank, State Street, Vor Shock
Premium
Weekend Updates
Clene, Lovesac, HDFC Bank, State Street, Vor Shock
5M ago
HDB
STT
Bj’s, Atlas, Academy, Vor, Global-e: Insider Shakeup
PremiumWeekend Updates
Bj’s, Atlas, Academy, Vor, Global-e: Insider Shakeup
5M ago
BJ
ASO
Vor Bio price target lowered to $31 from $32 at H.C. Wainwright
PremiumThe Fly
Vor Bio price target lowered to $31 from $32 at H.C. Wainwright
5M ago
VOR
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up
PremiumWeekend Updates
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up
6M ago
SG
VOR
Vor Bio price target raised to $15 from $9 at Wedbush
PremiumThe Fly
Vor Bio price target raised to $15 from $9 at Wedbush
6M ago
VOR
Vor Bio price target lowered to $40 from $55 at Stifel
PremiumThe FlyVor Bio price target lowered to $40 from $55 at Stifel
6M ago
VOR
Vor Bio price target lowered to $40 from $55 at Stifel
Premium
The Fly
Vor Bio price target lowered to $40 from $55 at Stifel
6M ago
VOR
Vor Biopharma: Solid Clinical Execution and Strengthened Balance Sheet Support Buy Rating and Long-Term Growth Outlook
Premium
Ratings
Vor Biopharma: Solid Clinical Execution and Strengthened Balance Sheet Support Buy Rating and Long-Term Growth Outlook
6M ago
VOR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >